1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ORGANIZATION
ORGANIZATION
- Hospitals Will “Respond Calmly” to Rule to Reduce Medical Fees Claimed by Facilities with Low Price Settlement Rates: Presidents of JHA, AJHA
February 19, 2014
- NPhA Objects to JPA Response on Rule to Reduce Dispensing Fees Claimed by Pharmacies with Low Price Settlement Rates
February 18, 2014
- MSD’s Alvarez Moved Up to Chair of PhRMA Japan Committee
February 13, 2014
- Prof. Tsuchiya Slams Kowa’s Livalo Trademark Suit
February 10, 2014
- July-September Generic Share at 43.1% under New Formula: JGA
February 6, 2014
- JPWA to File Notification to Form Cartel for Uniform Tax Display Method
January 31, 2014
- JPMA Drafting New Rules that Would Restrict Grants and Endowments by Drug Makers to Research Not Involving Their Own Products
January 28, 2014
- Medwatcher Raps Ministry Subcommittees’ Conclusion on HPV Vaccine Side Effects
January 27, 2014
- Generic Industry Can’t Afford “Backsliding” Following FY2014 NHI Pricing Reform: JGA President Yoshida
January 27, 2014
- Dr Teshirogi of JPMA Expresses Concern About Impact of New Price Reduction Rule on Stable Supplies of Long-Listed Drugs, Generics
January 17, 2014
- Generic Makers Likely to Disclose Payments to Medical Institutions from Early May
January 15, 2014
- JPWA Chair Weighs Cartel Deal to Unify Tax Display Methods after Sales Levy Hike
January 14, 2014
- Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
- Japan CRO Association Announces Report on Quality Assurance of Subcontracted Services
January 9, 2014
- New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
- New Price Cut Rule for Long-Listed Products Will Wreak Havoc on Pharmas: FPMAJ Chair
December 27, 2013
- Osaka Bio Fund to Invest 150 Million Yen in Genomix
December 26, 2013
- Mr Koshimizu of MREAC Expresses Concern about Increasing Number of MSLs at a Seminar on Recertification of Managers in Charge of MR Education
December 24, 2013
- Sanofi’s Moulding Picked as New Chair of EFPIA Japan
December 17, 2013
- FPMAJ Chief Renews His Calls to Institutionalize Premium
December 16, 2013
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…